Pharmstandard

Pharmstandard produces drugs for the treatment of cardiovascular diseases, diabetes mellitus, gastroenterological, neurological, infectious, oncological and other diseases. It includes five production enterprises, as well as a distributor, which concluded government contracts in the amount of more than 30.7 billion rubles in 2017.

Aktivs

By the beginning of 2010, Pharmstandart owned four pharmaceutical plants and one factory for the production of medical devices and instruments. More than 240 names of medicines are produced at the company's factories (about 90 names are included in the List of Vital Drugs (VED)). The company's capacity is more than 1.3 billion packages per year.

• Pharmstandard-Ufavita in Ufa. The plant was founded in 1916. General Director - Vladimir Kreiman. The number of employees is 1,400 people. Main brands: Complivit, Biosulin, Rastan, Neipomax, Phosphogliv.
• Pharmstandard-Phytopharm-NN in Nizhny Novgorod
• Pharmstandard-Tomskhimpharm in Tomsk. The plant was founded in 1913. General Director - Pavel Smachkov. The number of employees is over 600 people. Main brands: Arbidol, Amiksin, Imudon, Termikon, IRS-19.
• Pharmstandard-Lexredstva in Kursk. The plant was founded in 1922. General Director - Evgeny Prokhoda. The number of employees is over 1450 people. Main brands: Arbidol, Pentalgin, Phosphogliv.
• Tyumen plant of medical equipment and tools. The plant was founded in 1962. General Director - Nizovtsev Alexander. The main specialization of the plant is single-use medical products (needles, syringes, droppers, catheters, diuretics), sterilization equipment (steam sterilizers), aquadistillators, water collectors.

• 37.5% in Kirov Plasma (since March 2017).

History

2022

Opening a company for the production of blood products

On November 10, 2022, Pharmstandard registered a new company in Moscow, which was named Pharmstandard Plasma. Its main activity is the production of medicines, namely blood products. Read more here.

Investing 1.9 billion rubles in doubling paracetomol production

As it became known in May 2022, xxPharmstandartart will invest 1.9 billion rubles to double the production of paracetomol at the Kursk plant (OJSC Pharmstandard-Leksredstva). This decision of the company was reported by the press service of the administration of the Kursk region following the meeting of the governor of the region Roman Starovoit with the general director of Pharmstandard Vladimir Kreiman. Read more here.

2021: Purchase of 49% of the developer of medical IT systems "Tsifromed"

At the end of April 2021, the Federal Antimonopoly Service (FAS) of Russia announced the approval of a deal to sell 49% of Digital Medical Services LLC (Tsifromed) to the National Digital Health System (NCSZ). The financial and other terms of the agreement were not disclosed. Read more here.

2018: Victor Kharitonin is the sole owner

The main owner of Pharmstandard Viktor Kharitonin consolidates the entire business of the company, which is one of the largest suppliers for public procurement. His long-time partner Yegor Kulkov resigned from the shareholders of Pharmstandard. Market participants associate this decision with the risks of the company losing administrative resources. They estimate Mr. Kulkov's share at 16 billion rubles^[1].

Yegor Kulkov, partner of the main owner of Pharmstandard Viktor Kharitonin, has lost the status of a beneficiary of the company, its press service said. Pharmstandard is controlled by the Cypriot Augment Investments Ltd, the sole owner of which was Mr. Kharitonin. The company did not comment on the reasons for the withdrawal of Mr. Kulkov from the shareholders, as well as disclose what share belonged to him.

2017: Participation in the creation of the joint venture "Kirov Plasma"

The National Immunobiological Company, Pharmstandard and Kedrion Biopharma (Italy) signed an agreement on the creation of Kirov Plasma joint-stock company in March 2017. The company will develop and implement a program for the production of medicinal products obtained from human blood plasma in the Russian Federation on the basis of the Kirov plant. The share of Kedrion Biopharma in the authorized capital is 25%, Natsimbio and Pharmstandard - 37.5% for each company. For more details, see "Kirov Plasma."

Подписание проходило в здании Ростеха в присутствии генерального директора Госкорпорации Sergey Chemezov Acting Governor of the Kirov Region Igor Vasiliev.

2016: FAS rejected R-Pharm's claims against BIOCAD and Pharmstandard

See P-Pharm for details of the organization dispute.

2013: OTC business spun off into Otisipharm

In 2013, Pharmstandard separated the over-the-counter business into a separate company Otisipharm. Augment Investments is consolidating its shares.

2009: Only Russian member of IPEC Europe

In 2009, Pharmstandard became the first and only Russian member of the International Council of Manufacturers, Distributors and Consumers of Active Pharmaceutical Ingredients (Excipients) in Europe (IPEC Europe). In the same year, the company implemented an operation to implement a specialized IP solution for the central office and factories.

2008: Exclusive for distribution of Latvian Mildronat

In 2008, Pharmstandard entered into an agreement with the Latvian company Grindex (Latvia) for the exclusive distribution and promotion of Mildronat, is mastering the production of Afobazol, and is introducing the genetically engineered drug Neipomax into production.

2007

Joint production with the French at Tomskhimpharm

Since 2007, Pharmstandard has been actively working with foreign partners: for example, at Tomskhimpharm, together with Solvay Pharma (France), the production of IRS19 and Imudon drugs has begun.

Initial placement on RTS and LSE

On May 4, 2007, during a public offering (Initial Public Offering, IPO), the company placed its shares in the Russian Trading System (RTS) and Global Depository Receipts (GDR) on the London Stock Exchange (LSE). Investors showed interest in the company's shares, and the offering passed along the upper limit of the established range - $58.2 per share and $14.55 per depository receipt. The company's capitalization following the IPO amounted to $2.2 billion.

Pharmstandard placed 40% of the authorized capital on Russian and London exchanges, having withdrawn $880 million before the exercise of the option. Citi and UBS Investment Bank became global co-coordinators of the placement. Pharmstandard is the first Russian pharmaceutical company whose shares are listed on the international market.

2006: Purchase of "Masterlek"

By 2006, the company spent more than $70 million on bringing production to compliance with international GMP quality standards.

In 2006, Pharmstandard bought Masterlek, which had 15 well-known brands in its assets. In particular, the rights to Arbidol, Amiksin and Flukostat were obtained. By this time, the holding's production capacity exceeded 1 billion packages per year, all forms of medicines (tablets, suspensions, capsules, sprays) were produced at Pharmstandard's factories. By the end of the year, Arbidol came out on top in sales in Russia, overtaking Viagra and hawthorn tincture.

In 2006, the company launched several more high-tech drugs into production: the first growth hormone in Russia, Rastan, developed at the Institute of Bioorganic Chemistry, and the genetically engineered human insulin Biosulin. Pharmstandard is the largest Russian manufacturer of insulin. The company's capacity would be enough to meet 100% of the needs of Russians for this drug, but it still Russia imports most of the insulin from abroad.

2005: Purchase of Tyumen Medical Equipment Plant

In 2005, Pharmstandard bought the Tyumen Medical Equipment and Tools Plant.

2003: Abramovich's structures buy up pharmaceutical manufacturers

Pharmstandard was founded in 2003 by Profit House (the structure of Millhouse Capital, which managed the assets of Roman Abramovich). At that time, the company owned only two Russian pharmaceutical plants: Phytopharm-NN in Nizhny Novgorod and Ufavita in Ufa. Five more were bought from the American pharmaceutical giant ICN Pharmaceuticals: October in St. Petersburg, Marbiopharm in Yoshkar-Ola, Lexredstva in Kursk, Polypharm in Chelyabinsk and Tomskhimpharm in Tomsk.

Subsequently, three plants for various reasons were sold or closed: October (inconveniently located in the very center of the city), Marbiopharm (focused on the secondary production of substances for Pharmstandard's strategy), Polypharm (required too much investment).

Awards and Ratings

In 2005, the company took 1st place in the ranking of Russian pharmaceutical manufacturers. Arbidol, which is part of the company's portfolio, took 1st place in sales in 2007 on the Russian market of over-the-counter drugs.

In 2007, Pharmstandard was awarded the title "Company of the Year" and received first place in the ranking of Russian manufacturers compiled by the Center for Market Research "Pharmexpert."

At the beginning of 2008, Pharmstandard became one of the hundred fastest growing companies in Europe according to BusinessWeek experts, took first place in retail sales in Russia and second among operators of the Russian pharmaceutical market. The company was included in the list of backbone enterprises in Russia, which, if necessary, will be provided with state support.

In 2008, Pentalgin won the PEOPLE'S MARK/MARK No. 1 award in Russia in the category "Painkiller." In 2009, Complivit won in the Vitamins category.

Notes